Erlotinib combined with atezolizumab (anti‐PD‐L1 antibody) in 28 NSCLC patients also achieved a high ORR of 75% and a disease control rate of 90%, demonstrating robust therapeutic effects. This evidence concerns the gene CD274 and non-small cell lung carcinoma.